As part of the Expert Insights webinar series, Valid Insight brought together payers from US, Czechia and Italy to discuss key aspects of real-world evidence (RWE) and the way in which industry can use RWE to optimise market access and pricing activities. Find out more in our white paper.
Cell and gene therapies come with their own market access challenges, from both the payer and industry perspective. This white paper highlights the key factors and strategies that market access teams should consider to optimise market access for cell and gene therapies.
With a global economic recession expected as a result of the COVID-19 pandemic, the first webinar of our Expert Insights series brought together a panel of payers and industry representatives to discuss the impact that this will have on pharmaceutical pricing, reimbursement and market access. This white paper summarises the discussions that took place. Inside, […]
Collaboration, communicating value and building trust are essential strategic outputs that help to drive engagement with payers. To gain insight into how to improve the partnership between industry and payers, read our white paper.
Discover the current and future impact of the coronavirus (COVID-19) pandemic on business continuity and gain insight into the potential future direction of market access and healthcare post-COVID-19.
As value-based pricing becomes a popular model within life sciences industries, with it comes uncertainties and concerns for payers, which need considering.
It’s more important than ever to communicate your product’s value story. Gain expert insight and guidance to help you define the price of your product.
In today’s pharmaceutical landscape, what exactly does the tendering process entail? What impact is it having on competition in the market? What risks does it impose? And what does it mean to play the pricing game? This white paper provides the answers to these questions as we discuss the role of tendering, its importance, but also the risks to be aware of.
What are the opportunities and benefits real-world evidence and real-world data offer? What challenges do they present? And how can we overcome them to enhance your market access strategy?
This white paper provides evidence-backed answers to the industry’s most burning questions